Selecting the optimum dose for a new soft gelatin capsule formulation of Saquinavir [1]

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 19, Issue 2, 1998, Pages 195-197

  Lalezari, J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SAQUINAVIR;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CAPSULE; DRUG FORMULATION; DRUG POTENCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0031688515     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199810010-00015     Document Type: Letter

References (6)